KW-6356 (Sipagladenant) 1 mg – 60 tablets
research-grade
tablets
in a sealed bottle. Sipagladenant (KW-6356) is a selective adenosine A2A receptor antagonist/inverse agonist investigated in laboratory models of basal ganglia circuitry, cAMP signaling, dopaminergic modulation and neuroplasticity.
Research Use Only:
All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
Purity
High-purity research grade
Content
1 mg Sipagladenant per tablet
Total tablets
60 tablets (total 60 mg per bottle)
Packaging
Sealed tablet bottle
Storage
Store in a cool, dry place at room temperature; protect from light.
Molecular formula
C20H19N3O4S
Molecular weight
≈ 397.45 g·mol⁻¹
IUPAC name
N-(4-(furan-2-yl)-5-(tetrahydro-2H-pyran-4-carbonyl)thiazol-2-yl)-6-methylnicotinamide
Research Overview
KW-6356 is applied in experimental systems to interrogate A2A-receptor control of basal ganglia networks and cAMP/PKA signaling. Research frequently examines dopaminergic modulation, synaptogenesis markers, transcriptional programs linked to plasticity, and resilience under stress paradigms in vitro and in vivo.
Primary Research Areas
-
A2A adenosine receptor signaling: Antagonism/inverse agonism and cAMP pathway readouts.
-
Basal ganglia circuitry: Striatal pathway modulation in neuronal models.
-
Dopaminergic modulation: Interactions with D2-linked signaling and synaptic endpoints.
-
Neuroplasticity & synaptogenesis: Spine density and synaptic protein markers under controlled conditions.
